Table 3.
Intraoperative donor ischemic times and laboratory values
| Parameter | Donor 1 | Donor 2 | Donor 3 | Donor 4 | Donor 5 | Donor 6 | Donor 7 | Donor 8 | Donor 9 | Donor 10 | Donor 11 | Donor 12 | Donor 13 | Donor 14 | Donor 15 | Donor 16 | Donor 17 | Donor 18 | Mean ± SD for all donors | P-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WLST to agonal phase, min | 5 | 0 | 1 | 2 | 1 | 1 | 12 | 3 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2.17 ± 2.71 | |
| Agonal phase to asystole, min | 14 | 14 | 15 | 23 | 16 | 9 | 20 | 3 | 14 | 14 | 12 | 18 | 13 | 7 | 3 | 16 | 16 | 11 | 13.22 ± 5.23 | |
| WLST to asystole, min | 19 | 14 | 16 | 25 | 17 | 10 | 32 | 6 | 14 | 15 | 13 | 20 | 15 | 8 | 5 | 18 | 18 | 12 | 15.39 ± 6.51 | |
| WLST to skin incision, min | 29 | 19 | 21 | 25 | 23 | 16 | 38 | 11 | 20 | 20 | 18 | 25 | 20 | 14 | 11 | 23 | 24 | 24 | 21.17 ± 6.42 | |
| Skin incision to CPB, min | 12 | 9 | 12 | 12 | 9 | 11 | 11 | 12 | 7 | 9 | 9 | 12 | 9 | 7 | 8 | 10 | 6 | 0 | 9.17 ± 3.00 | |
| Return of cardiac activity, min | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1.0 ± 0.0 | |
| Total donor CPB time, min | 40 | 32 | 35 | 39 | 68 | 33 | 115 | 119 | 84 | 64 | 38 | 118 | 102 | 100 | 141 | 130 | 109 | 231 | 88.78 ± 51.76 | |
| Functional WIT, min | 36 | 28 | 32 | 35 | 31 | 26 | 37 | 20 | 27 | 28 | 26 | 35 | 27 | 20 | 17 | 31 | 28 | 23 | 28.17 ± 5.74 | |
| Total WIT, min | 41 | 28 | 33 | 37 | 32 | 27 | 49 | 23 | 27 | 29 | 27 | 37 | 29 | 21 | 19 | 33 | 30 | 24 | 30.33 ± 7.36 | |
| Total CIT, min | 78 | 70 | 85 | 80 | 84 | 80 | 65 | 68 | 70 | 86 | 67 | 69 | 95 | 71 | 76 | 117 | 85 | 68 | 78.56 ± 12.75 | |
| Lactate at beginning of CPB, mmol/L | 7.7 | 8.3 | 11.3 | 10.1 | 10.2 | 7.3 | 10.7 | 9.4 | 11.0 | 8.1 | 9.9 | 8.6 | 9.6 | 8.7 | 6.9 | 9.8 | 8.6 | 12.6 | 9.4 ± 1.5 | P < .0001 |
| Lactate at end of CPB, mmol/L | 10.2 | 7.7 | 8.2 | 5.9 | 4.8 | 7.6 | 2.4 | 8.1 | 2.5 | 3.1 | 10.3 | 4.1 | 3.9 | 3.9 | 3.4 | 3.5 | 2.3 | 3.4 | 5.3 ± 2.7 | |
| K+ at beginning of CPB, mmol/L | 7.2 | 9.7 | 6.4 | 6.6 | 4.6 | 7.7 | 9.0 | 5.8 | 4.5 | 6.8 | 4.4 | 7.9 | 6.2 | 6.2 | 3.7 | 7.4 | 4.2 | 9.5 | 6.5 ± 1.8 | P < .0001 |
| K+ at end of CPB, mmol/L | 3.5 | 4.8 | 4.0 | 4.3 | 5.2 | 4.3 | 4.4 | 3.8 | 4.2 | 4.0 | 4.7 | 3.9 | 4.4 | 4.2 | 3.9 | 4.5 | 3.6 | 4.2 | 4.2 ± 0.4 | |
| Hgb at beginning of CPB, g/dL | 6.0 | 6.0 | 6.0 | 6.4 | 6.1 | 6.0 | 6.9 | 7.1 | 8.3 | 6.5 | 6.6 | 6.6 | 8.1 | 6.0 | 6.9 | 7.5 | 7.8 | 6.8 | 6.8 ± 0.7 | P < .001 |
| Hgb at end of CPB, g/dL | 8.0 | 9.8 | 9.3 | 8.1 | 7.4 | 6.4 | 10.1 | 6.0 | 8.9 | 7.6 | 8.8 | 7.0 | 10.2 | 7.9 | 9.2 | 8.2 | 8.4 | 6.4 | 8.2 ± 1.3 | |
| Transfused pRBC, units | 2 | 2 | 2 | 2 | 7 | 2 | 2 | 4 | 0 | 2 | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 1 | 2.0 ± 1.5 |
SD, Standard deviation; WLST, withdrawal of life-sustaining therapy; CPB, cardiopulmonary bypass; WIT, warm ischemic time; CIT, cold ischemic time; HgB, hemoglobin; pRBC, packed red blood cells.